ClinicalTrials.gg
RecruitingNCT07609602PEMPSUpdated Oct 29, 2026

The Psychological Effects of Miscarriage Prediction Score: A Prospective Study

An interventional study of Miscarriage prediction score and Will not receive miscarriage prediction score in Early Pregnancy Bleeding, sponsored by King's College Hospital NHS Trust. Recruiting at 1 site in United Kingdom. Open to female participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by King's College Hospital NHS Trust · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Oct 29, 2026Now RecruitingFirst site in United Kingdom+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
372
Allocation
Randomized
Ages
16 Years and older
Sex
Female
01

Study summary

Patients Under 12 Weeks Pregnant With a Single Ongoing Pregnancy Attending the EPU Will be Randomly Assigned to Receive Their Personalised Miscarriage Risk Score or Not. The Study Explores Whether Sharing This Score Affects Anxiety and Whether Patients Find the Information Helpful and Acceptable. (PEMPS)

Read the detailed description

The PEMPS study is a prospective, randomised controlled investigation designed to evaluate the psychological impact of providing individualised miscarriage risk estimates to patients in early pregnancy. The study population comprises individuals attending an Early Pregnancy Unit (EPU) with a confirmed single ongoing intrauterine pregnancy under 12 weeks' gestation. Participants will be randomly allocated in a 1:1 ratio to either receive their personalised miscarriage risk score (intervention group) or to receive standard care without disclosure of such a score (control group).

Randomisation will be implemented using a computer-generated allocation sequence with appropriate allocation concealment to minimize selection bias. The personalised miscarriage risk score will be derived using a validated predictive model incorporating relevant clinical and ultrasound parameters routinely collected during EPU assessment. The methodology underlying the risk calculation will remain consistent across participants to ensure comparability and reproducibility.

Participants in the intervention arm will be provided with their individualised risk estimate in a standardised format, accompanied by a brief explanation to support interpretation. Care will be taken to ensure that the communication approach is clear, non-directive, and does not include additional counselling beyond standard clinical practice. Participants in the control arm will receive routine clinical information and follow-up as per standard EPU protocols, without access to the calculated risk score.

The primary objective of the study is to determine whether disclosure of a personalised miscarriage risk score influences patient-reported anxiety levels in early pregnancy, assessed using a validated questionnaires on Day 0 and Day 7. The secondary objective is patient acceptability of the study using qualitative feedback on Day 7.

02

Conditions studied

  • Early Pregnancy Bleeding
03

In context

Lead sponsor

King's College Hospital NHS Trust is the lead sponsor of 171 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have capacity to understand the study and to provide signed and dated .
  • Willing to comply with all study procedures and be available for the duration of the study including consenting to follow up of the pregnancy outcome by letter, phone or email according to individual preference.
  • Age 16 years or over
  • Single live ongoing intrauterine pregnancy less than 12 weeks gestation

Exclusion criteria

Exclusion Criteria:

Women with pregnancies of unknown location, ectopic pregnancies or early pregnancy prior to an embryo being seen or an embryo without a heartbeat.

  • Multiple pregnancies
  • Those undergoing assessment or treatment for a psychological condition by a psychiatrist
  • Those who do not speak English or require a translator
  • Women who have taken part in another clinical trial in the last 3 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
372 participants (estimated)

Study arms

  • Experimental
    Receive Miscarriage Prediction Score

    These participants will receive their miscarriage prediction score

    Other: Miscarriage prediction score

  • Experimental
    Will Not Receive Miscarriage Prediction Score

    These patients will not receive a Miscarriage Prediction Score

    Other: Will not receive miscarriage prediction score

Interventions

  • OtherMiscarriage prediction score

    Half of the patients will receive a uniquely calculated miscarriage prediction score based on symptoms and individual characteristics

  • OtherWill not receive miscarriage prediction score

    These patients will not receive a miscarriage prediction score

06

What researchers measure

Primary outcomes

  1. To measure the psychological effects of the miscarriage prediction model

    The study will measure patients' psychological wellbeing objectively using a composite psychological distress score. This composite score is derived by combining the Hospital Anxiety and Depression Scale (HADS) and Penn State Worry Questionnaire (PSWQ) scores. The HADS score has a minimum score of 0 (Low Anxiety/Depression) and maximum score of 42 (High Anxiety/Depression). The PSWQ has a minimum score of 16 (Low Worry) and a maximum score of 80 (High Worry). The composite score will therefore have a minimum score of 16 (low psychological distress) and a maximum score of 122 (greater psychological distress). These questionnaires will be completed on day 0 and day 7 by patients in both treatment arms and a composite score will be calculated.

    Time frame: 7 days

  2. To measure the psychological effects of the miscarriage prediction model

    The study will measure patients' psychological wellbeing objectively using the Penn State Worry Questionnaire (PSWQ) score. The Penn State Worry Questionnaire has a minimum score of 16 (Low Worry) and a maximum score of 80 (High Worry). This questionnaire will be completed on day 0 and day 7 by patients in both treatment arms.

    Time frame: 7 days

Secondary outcomes

  1. Acceptability of receiving miscarriage prediction score

    Acceptability will be assessed by sending patients who receive a miscarriage prediction score the following questions: 1. Did receiving the miscarriage prediction score help you feel more informed and prepared about your pregnancy outcome? (Yes/No, with an optional text box for further explanation.) 2. Would you recommend that other women in early pregnancy receive a miscarriage prediction score as part of their care? (Yes/No, with an optional explanation.)

    Time frame: 7 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — The investigators do not plan to share IPD. The informed consent obtained from participants and ethics approval does not include provisions for broad data sharing beyond the immediate research team. As such, making IPD available outside the scope of the original study would not align with the consent provided.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2026 (actual). Primary completion is estimated for Jul 2027, 13 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: start Jun 2026 → May 2026, primary completion Jun 2027 → Jul 2027 and completion Jun 2028 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
May 27, 2026
StartActual
May 29, 2026was Jun 2026
Primary completionEst.
Jul 1, 2027was Jun 2027
CompletionEst.
Jul 1, 2027was Jun 2028
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 29, 2026
Sites
1 site added — first site in United Kingdom
Show site
  • King's College Hospital · London, United Kingdom
Oct 29, 2026
Start date
Jun 1, 2026→May 29, 2026 (actual)
Oct 29, 2026
Primary completion
Jun 1, 2027→Jul 1, 2027
Oct 29, 2026
Study completion
Jun 1, 2028→Jul 1, 2027
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United Kingdom
    Show site
    • King's College Hospital · London, United Kingdom
    Start date Jun 1, 2026→May 29, 2026 (now actual)
    Primary completion Jun 1, 2027→Jul 1, 2027
    Study completion Jun 1, 2028→Jul 1, 2027
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07609602
Responsible party
Sponsor
First posted
May 27, 2026
Start date
May 29, 2026
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Eleanor Fleming, MBBS BSc MRCOG
Contact
eleanor.fleming@nhs.net
+4420 3299 3168
Jackie Ross
Contact
Jackie Ross, FRCOG
principal investigator · King's College Hospital NHS Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion